Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06514313
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-04
Brief Title:
Clinical Trial of VIM With VIT in Children With Relapsed and Refractory Soft Tissue Sarcoma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Phase II Randomized Controlled Clinical Trial of Mitoxantrone Hydrochloride Liposome Combined With Irinotecan and Vincristine VIM With VIT in Children With Relapsed and Refractory Soft Tissue Sarcoma
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Explore the efficacy and safety of mitoxantrone liposome combined with irinotecan and vincristine VIM in the treatment of relapsedrefractory soft tissue sarcoma in children
Detailed Description:
Children with relapsedrefractory soft tissue sarcoma who meet the inclusion criteria are randomly divided into VIM group and VIT group irinotecan vincristine temozolomide at 11 The efficacy and safety of the two groups are compared
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None